Download Free Anticancer Book in PDF and EPUB Free Download. You can read online Anticancer and write the review.

The author describes his treatment for brain cancer, challenges beliefs about the body's ability to heal, identifies the environmental and lifestyle factors that promote cancer growth, and outlines conventional and alternative therapies.
This unique volume traces the critically important pathway by which a "molecule" becomes an "anticancer agent. " The recognition following World War I that the administration of toxic chemicals such as nitrogen mustards in a controlled manner could shrink malignant tumor masses for relatively substantial periods of time gave great impetus to the search for molecules that would be lethal to specific cancer cells. Weare still actively engaged in that search today. The question is how to discover these "anticancer" molecules. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Second Edition describes the evolution to the present of preclinical screening methods. The National Cancer Institute's high-throughput, in vitro disease-specific screen with 60 or more human tumor cell lines is used to search for molecules with novel mechanisms of action or activity against specific phenotypes. The Human Tumor Colony-Forming Assay (HTCA) uses fresh tumor biopsies as sources of cells that more nearly resemble the human disease. There is no doubt that the greatest successes of traditional chemotherapy have been in the leukemias and lymphomas. Since the earliest widely used in vivo drug screening models were the murine L 1210 and P388 leukemias, the community came to assume that these murine tumor models were appropriate to the discovery of "antileukemia" agents, but that other tumor models would be needed to discover drugs active against solid tumors.
The past decades have seen major developments in the understanding of the cellular and molecular biology of cancer. Significant progress has been achieved regarding long-term survival for the patients of many cancers with the use of tamoxifen for treatment of breast cancer, treatment of chronic myeloid leukaemia with imatinib, and the success of biological drugs. The transition from cytotoxic chemotherapy to targeted cancer drug discovery and development has resulted in an increasing selection of tools available to oncologists. In this Special Issue of Pharmaceuticals, we highlight the opportunities and challenges in the discovery and design of innovative cancer therapies, novel small-molecule cancer drugs and antibody–drug conjugates, with articles covering a variety of anticancer therapies and potential relevant disease states and applications. Significant efforts are being made to develop and improve cancer treatments and to translate basic research findings into clinical use, resulting in improvements in survival rates and quality of life for cancer patients. We demonstrate the possibilities and scope for future research in these areas and also highlight the challenges faced by scientists in the area of anticancer drug development leading to improved targeted treatments and better survival rates for cancer patients.
Anticancer Treatments and Cardiotoxicity: Mechanisms, Diagnostic and Therapeutic Interventions presents cutting edge research on the adverse cardiac effects of both radiotherapy and chemotherapy, brought together by leaders in the field. Cancer treatment-related cardiotoxicity is the leading cause of treatment-associated mortality in cancer survivors and is one of the most common post-treatment issues among survivors of adult cancer. Early detection of the patients prone to developing cardiotoxicity, taking in to account the type of treatment, history and other risk factors, is essential in the fight to decrease cardiotoxic mortality. This illustrated reference describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment. In addition, new guidelines on imaging for the screening and monitoring of these patients are also presented. Anticancer Treatments and Cardiotoxicity is an essential reference for those involved in the research and treatment of cardiovascular toxicity. Provides algorithms essential for the use of imaging, and biomarkers for the screening and monitoring of patients Written by world-leading experts in the field of cardiotoxicity Includes high-quality images, case studies, and test questions Describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment
The book provides current knowledge and research on the presence and effects of anticancer drug residues in the aqueous environment and covers all relevant aspects of the presence of these residues in wastewaters and natural aquatic systems, where numerous analogies between their pharmacokinetics and pharmacodynamics in humans and their effects in the environment can be drawn. This book comprises of 18 chapters and represents the combined work of leading scientists from different research institutions from across the globe. We present the state of the art in the field of anticancer drug residues in the aquatic environment while being cognizant of the many challenges that remain.
Medicinal Chemistry of Anticancer Drugs, Second Edition, provides an updated treatment from the point of view of medicinal chemistry and drug design, focusing on the mechanism of action of antitumor drugs from the molecular level, and on the relationship between chemical structure and chemical and biochemical reactivity of antitumor agents. Antitumor chemotherapy is a very active field of research, and a huge amount of information on the topic is generated every year. Cytotoxic chemotherapy is gradually being supplemented by a new generation of drugs that recognize specific targets on the surface or inside cancer cells, and resistance to antitumor drugs continues to be investigated. While these therapies are in their infancy, they hold promise of more effective therapies with fewer side effects. Although many books are available that deal with clinical aspects of cancer chemotherapy, this book provides a sorely needed update from the point of view of medicinal chemistry and drug design. Presents information in a clear and concise way using a large number of figures Historical background provides insights on how the process of drug discovery in the anticancer field has evolved Extensive references to primary literature
This book explains how current medicines against cancer work and how we find new ones. It provides an easy-to-understand overview of current options to treat patients with cancer, which includes Surgery, Radiation therapy, Chemotherapy, Targeted therapy and Immunotherapy. The efficiency of all these treatments is limited by the capacity of cancer cells to escape therapy. This book explains the mechanisms of anti-cancer drug resistance and strategies to overcome it. The discovery and development process of a new drug is detailed beginning with the identification and validation of a therapeutic target, the identification of an inhibitor of the target and its subsequent preclinical and clinical development until its approval by regulatory authorities. Particular emphasis has been given to specific aspects of the development process including lead generation and optimization, pharmacokinetics, ADME analysis, pharmacodynamics, toxicity and efficacy assessment, investigational new drug (IND) and new drug application (NDA) and the design of clinical trial and their phases. The book covers many aspects of modern personalized oncology and discusses economic aspects of our current system of developing new medicines and its impact on our societies and on future drug research. The author of this book, Dr. Link counts with more than 20 years of experience in biomedical research reflected in numerous publications, patents and key note and plenary presentations at international conferences. Interested readers, students and teachers should read this book as it provides a unique way to learn/teach about basic concepts in oncology and anti-cancer drug research.
With the huge number of studies on nutrition and cancer available, it's impossible for a person to sort through them all to come up with practical recommendations. Now, Dr. David Khayat, a world-renowned oncologist, has done that hard work for you. In this international bestseller, Dr. Khayat provides easy-to-follow—and often surprising—guidelines on what are now known to be the foods most likely to reduce the risk of cancer. For those of a scientific bent, he explains what cancer is and how it develops. Bringing together his own research with that of other major cancer specialists, he breaks down what the studies mean, which ones provide the most solid evidence, and how to use their results in your and your family’s diet. Structured by the major food groups—as well as supplements, beverages, and exercise—The Anticancer Diet may surprise you by not disparaging red meat but alerting you to find out the source of your fish and suggesting sole over salmon. While highly recommending commercial pomegranate juice, it cautions people with fair hair and eyes against drinking orange juice. What stage of life a person is at will also affect what they should consume. Pregnant women, older women, men, and children may process foods differently. With numerous easy-to-read charts and tables along with a comprehensive food list at the back of the book, this accessible, user-friendly guide helps readers realize the power in their everyday choices.
This book summarizes the application of plant derived anticancer compounds as chemopreventives to treat several cancer types, focusing on the molecular mechanisms of action of phytocompounds and providing an overview of the basic processes at the cellular and molecular level that are involved in the progression of the cancer and can be employed in targeted preventive therapies. In addition, it highlights the development of novel anticancer drugs from plant sources using bioinformatics approaches. The compiled chapter data aids readers understanding of issues related to bioavailability, toxic effects and mechanisms of action of phytocompounds, and helps them identify the leads and utilize them against various cancer types effectively. Furthermore, it promotes the use of bioinformatics tools in medicinal plants to expedite their use in plant breeding programs to develop molecular markers to distinguish disease subtypes and predicting mutation, which in turn improves cancer diagnosis and prognosis, and to develop new lead compounds computationally. The book provides scientific verifications of plant compounds mechanisms of action against various cancers and offers useful information for students, teachers, and healthcare professionals involved in drug discovery, and clinical and therapeutic research.